Cita APA

adès, l., Girshova, L., Doronin, V., Díez Campelo, M., KAMBHAMPATI, S., & VALCARCEL, D. (2022). Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Citación estilo Chicago

adès, lionel, Larisa Girshova, Vadim Doronin, María Díez Campelo, SUMAN KAMBHAMPATI, y DAVID VALCARCEL. Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-risk MDS/chronic Myelomonocytic Leukemia or Low-blast-percentage AML. 2022.

Cita MLA

adès, lionel, et al. Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-risk MDS/chronic Myelomonocytic Leukemia or Low-blast-percentage AML. 2022.